ME00554B - KORIŠĆENJE IL-18 INHIBITORA ZA LIJEČENJE l/ILI PREVENCIJU ATEROSKLEROZE - Google Patents

KORIŠĆENJE IL-18 INHIBITORA ZA LIJEČENJE l/ILI PREVENCIJU ATEROSKLEROZE

Info

Publication number
ME00554B
ME00554B MEP-2008-640A MEP64008A ME00554B ME 00554 B ME00554 B ME 00554B ME P64008 A MEP64008 A ME P64008A ME 00554 B ME00554 B ME 00554B
Authority
ME
Montenegro
Prior art keywords
atherosclerosis
prevention
treatment
inhibitors
medicament
Prior art date
Application number
MEP-2008-640A
Other languages
English (en)
Inventor
Yolande Chvatchko
Alain Tedgui
Ziad Mallat
Original Assignee
Serono Lab
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab, Inst Nat Sante Rech Med filed Critical Serono Lab
Publication of MEP64008A publication Critical patent/MEP64008A/xx
Publication of ME00554B publication Critical patent/ME00554B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Ovaj pronalazak se odnosi na inhibitor IL-18 za proizvodnju medikamenta za lečenje i/ili prevenciju ateroskleroze.
MEP-2008-640A 2000-05-05 2001-04-30 KORIŠĆENJE IL-18 INHIBITORA ZA LIJEČENJE l/ILI PREVENCIJU ATEROSKLEROZE ME00554B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00109606 2000-05-05
PCT/EP2001/004843 WO2001085201A2 (en) 2000-05-05 2001-04-30 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis

Publications (2)

Publication Number Publication Date
MEP64008A MEP64008A (en) 2011-12-20
ME00554B true ME00554B (me) 2012-03-20

Family

ID=8168631

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-640A ME00554B (me) 2000-05-05 2001-04-30 KORIŠĆENJE IL-18 INHIBITORA ZA LIJEČENJE l/ILI PREVENCIJU ATEROSKLEROZE

Country Status (33)

Country Link
US (1) US20040076628A1 (me)
EP (1) EP1278540B1 (me)
JP (1) JP5122053B2 (me)
KR (2) KR100798545B1 (me)
CN (2) CN1250286C (me)
AR (1) AR035640A1 (me)
AT (1) ATE395075T1 (me)
AU (2) AU2001267390B2 (me)
BG (1) BG65881B1 (me)
BR (1) BRPI0110506B8 (me)
CA (1) CA2407895C (me)
CY (1) CY1110385T1 (me)
CZ (1) CZ300792B6 (me)
DE (1) DE60134009D1 (me)
DK (1) DK1278540T3 (me)
EA (2) EA007014B1 (me)
EE (1) EE05056B1 (me)
ES (1) ES2305082T3 (me)
HK (2) HK1055681A1 (me)
HR (1) HRP20020828A2 (me)
HU (1) HU229375B1 (me)
IL (2) IL152567A0 (me)
ME (1) ME00554B (me)
MX (1) MXPA02010895A (me)
NO (1) NO329821B1 (me)
PL (1) PL209371B1 (me)
PT (1) PT1278540E (me)
RS (1) RS50926B (me)
SI (1) SI1278540T1 (me)
SK (1) SK287761B6 (me)
UA (2) UA78492C2 (me)
WO (1) WO2001085201A2 (me)
ZA (1) ZA200208228B (me)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102206277A (zh) * 2000-02-10 2011-10-05 雅培制药有限公司 结合人白介素-18的抗体及制备和使用方法
DK1355668T3 (da) * 2001-01-29 2008-05-05 Serono Lab Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
WO2002096456A1 (en) 2001-05-25 2002-12-05 Ares Trading S.A. Use of il-18 inhibitors for treating or preventing cns injuries
US6797727B2 (en) 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
SI1487541T1 (sl) 2002-03-22 2009-02-28 Serono Lab Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
ATE399872T1 (de) * 2003-03-11 2008-07-15 Serono Lab Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten
WO2004101617A1 (en) 2003-05-13 2004-11-25 Applied Research Systems Ars Holding N.V. Active variants of the il-18 binding protein and medical uses thereof
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20080044404A1 (en) * 2004-04-15 2008-02-21 Anna Cederholm Annexin V for Preventing Atherothrombosis and Plaque Rupture
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
DK2267024T3 (da) 2005-06-03 2012-06-25 Ares Trading Sa Fremstilling af rekombinant II-18 bindingsprotein
SI1891088T1 (sl) 2005-06-10 2012-02-29 Ares Trading Sa Postopek za äśiĺ äśenje il-18 vezavnega proteina
EP2609117B1 (en) 2010-08-25 2015-09-16 F.Hoffmann-La Roche Ag Antibodies against il-18r1 and uses thereof
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
HUE055608T2 (hu) 2013-09-05 2021-12-28 Ab2 Bio Sa IL-18-kötõ fehérje (IL-18BP) gyulladásos betegségekben
AU2016227644B2 (en) 2015-03-05 2022-06-16 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) and antibodies in inflammatory diseases
CN110273591B (zh) 2019-08-13 2023-12-12 上海杉脉电子科技发展有限公司 一种单动力微型智能锁
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途
CN112972655A (zh) * 2021-04-16 2021-06-18 武汉大学 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
WO2000012555A1 (fr) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Proteine de liaison de l'interleukine 18

Also Published As

Publication number Publication date
BG107218A (bg) 2003-06-30
CN1841066A (zh) 2006-10-04
EA200201175A1 (ru) 2003-04-24
HUP0301991A3 (en) 2006-11-28
IL152567A0 (en) 2003-05-29
ES2305082T3 (es) 2008-11-01
NO20025307L (no) 2002-12-18
BRPI0110506B8 (pt) 2021-05-25
HK1094909A1 (en) 2007-04-13
YU82602A (sh) 2006-01-16
PL209371B1 (pl) 2011-08-31
JP5122053B2 (ja) 2013-01-16
CA2407895A1 (en) 2001-11-15
SK15562002A3 (sk) 2003-05-02
ATE395075T1 (de) 2008-05-15
UA87658C2 (uk) 2009-08-10
CZ20023644A3 (cs) 2003-03-12
EE05056B1 (et) 2008-08-15
EE200200620A (et) 2004-06-15
HK1055681A1 (en) 2004-01-21
JP2003532685A (ja) 2003-11-05
KR20030016254A (ko) 2003-02-26
CA2407895C (en) 2012-12-18
BRPI0110506B1 (pt) 2015-05-19
MEP64008A (en) 2011-12-20
EP1278540A2 (en) 2003-01-29
CY1110385T1 (el) 2015-04-29
EA007014B1 (ru) 2006-06-30
HU229375B1 (en) 2013-11-28
CN1434722A (zh) 2003-08-06
KR20070073989A (ko) 2007-07-10
US20040076628A1 (en) 2004-04-22
NO20025307D0 (no) 2002-11-05
PT1278540E (pt) 2008-07-03
RS50926B (sr) 2010-08-31
CN1841066B (zh) 2012-08-29
SK287761B6 (en) 2011-09-05
AR035640A1 (es) 2004-06-23
EP1278540B1 (en) 2008-05-14
EA005410B1 (ru) 2005-02-24
BR0110506A (pt) 2003-04-01
DK1278540T3 (da) 2008-07-21
DE60134009D1 (de) 2008-06-26
BG65881B1 (bg) 2010-04-30
CZ300792B6 (cs) 2009-08-12
IL152567A (en) 2010-12-30
PL365697A1 (en) 2005-01-10
KR100798545B1 (ko) 2008-01-28
WO2001085201A2 (en) 2001-11-15
NO329821B1 (no) 2010-12-27
UA78492C2 (en) 2007-04-10
HUP0301991A2 (hu) 2003-09-29
EA200401183A1 (ru) 2004-12-30
CN1250286C (zh) 2006-04-12
ZA200208228B (en) 2005-07-27
SI1278540T1 (sl) 2008-10-31
AU6739001A (en) 2001-11-20
HRP20020828A2 (en) 2004-12-31
AU2001267390B2 (en) 2005-09-22
MXPA02010895A (es) 2003-03-27
WO2001085201A3 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
ME00554B (me) KORIŠĆENJE IL-18 INHIBITORA ZA LIJEČENJE l/ILI PREVENCIJU ATEROSKLEROZE
ME00548B (me) Korišćenje inhibitora il-18 za liječenje i/ili prevenciju perifernih vaskularnih bolesti
MEP90508A (en) New pharmaceutical composition
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
BR0317715A (pt) Composições e processos de uso de collajolie
BR9809819A (pt) Compostos e métodos para a inibição da expressão de vcam-1
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
PT1002795E (pt) Pirimidinas inibidoras da replicacao do hiv
SE9802333D0 (sv) Novel combination
UY27972A1 (es) Derivados de hidantoína
WO2003042246A3 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
HN2003000227A (es) Inhibidores de quinasas
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
ATE332129T1 (de) Behandlung der akne mit lipoxygenase inhibitoren
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
TR200502508T2 (tr) IL-18 İnhibitörlerinin kullanımı.
EE200300248A (et) GABA agonistide ja sorbitooldehüdrogenaasi inhibiitorite kombinatsioon
HUP0401854A2 (hu) COX-2 inhibitorokat és aszpirint tartalmazó kombinációk
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
DE60329326D1 (de) Tace inhibitoren
NO20015892L (no) Inhibitorer av metallproteinaser
NO20023956L (no) Priperidin- og piperazinsubstituerte N-hydroksyformamider som inhibitorer av metalloproteinaser
ECSP034634A (es) Inhibidores de la farnesil transferasa